Acquisition of UPADACITINIB ORAL (AUE 202505041) from Lab. Abbvie for ULSASI for the year 2026

This tender concerns the acquisition of the oral medication Upadacitinib, identified by the code AUE 202505041. The procurement is specifically from the laboratory Abbvie and is intended for ULSASI (Unidade Local de Saúde do Alto Minho, I.P. - Local Health Unit of Alto Minho, IP) for the year 2026. Upadacitinib is a Janus kinase (JAK) inhibitor used to treat certain autoimmune and inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. This tender ensures that ULSASI will have access to this important medication for its patients throughout 2026. The procurement process will likely involve direct negotiation or a specific procedure to acquire this drug from the authorized manufacturer or distributor. The focus is on securing a reliable supply of this specific pharmaceutical product to meet patient needs. The tender details will outline the quantities required, delivery schedules, and contractual terms necessary for the supply of Upadacitinib.

This is a supplies contract in the health and medical services, Research and general supplies sectors, with a focus on Laboratories. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 11,286.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.